Please assess the completion status of the following clinical trial:

Trial Title: Sirolimus Injections for Autoimmune Scleritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
INCLUSION CRITERIA:~1. Participant has the ability to understand and sign the informed consent document.~2. Participant is 18 years of age or older.~3. Participant has a diagnosis of active, autoimmune, non-necrotizing, anterior scleritis.~4. Participant, if currently taking immunosuppressive medications, is on a stable regimen of immunosuppressive medications (no increase and/or start of new immunosuppressive medications) over the last four weeks.~5. Participant has tried therapy such as oral non-steroidal anti-inflammatory drugs (NSAIDs), or oral or topical corticosteroids or immunosuppressive medication at any time in the past to control scleritis flares, or has intolerance or contraindications to these medications.~6. Participant is willing and able to comply with the study procedures.~7. Female participants of childbearing potential must not be pregnant or breast-feeding, have a negative pregnancy test at screening and must be willing to undergo pregnancy tests throughout the study.~8. Both female participants of childbearing potential and male participants able to father children must have (or have a partner who has) had a hysterectomy or vasectomy, be completely abstinent from intercourse or must agree to practice two acceptable methods of contraception throughout the course of the study and for four months after the last investigational product injection. Acceptable methods of contraception include: hormonal contraception (i.e., birth control pills, injected hormones, dermal patch or vaginal ring), intrauterine device, barrier methods (diaphragm, condom) with spermicide, or surgical sterilization (tubal ligation).~EXCLUSION CRITERIA:~1. Participant has a significant active intraocular infection in either eye that requires antibiotic treatment.~2. Participant has an active serious infection or a history of recurring serious infections such as human immunodeficiency virus (HIV) or syphilis that in the best medical judgment of the investigators would pose unnecessary risk to the participant.~3. Participant has active joint or systemic inflammation requiring immediate addition or increase in systemic anti-inflammatory medications.~4. Participant is taking systemic azole anti-fungal medication (e.g., ketoconazole, voriconazole, itraconazole).~STUDY EYE ELIGIBILITY CRITERIA:~The participant must have at least one eye meeting all inclusion criteria and none of the exclusion criteria listed below.~STUDY EYE INCLUSION CRITERIA:~1. Participant has anterior scleritis with greater than or equal to 1 plus in at least one quadrant of the study eye.~2. Participant has visual acuity in the study eye of 20/640 or better.~3. Participant agrees not to undergo elective intraocular surgery in the study eye (e.g., cataract extraction) for three months after the last injection.~4. Participant has not received a periocular or intravitreal injection in the study eye in the last six weeks.~STUDY EYE EXCLUSION CRITERIA:~1. Participant has necrotizing scleritis in the study eye.~2. Participant had intraocular surgery in the study eye in the last four weeks.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sirolimus (Type: EXPERIMENTAL): Participants will receive a15 μL (660 μg) subconjunctival injection of sirolimus in the study eye at baseline if a single quadrant or two adjacent quadrants are involved. If greater than two quadrants are involved (i.e., 3 or 4 quadrant involvement) or two non-adjacent quadrants are involved, two 15 μL (660 μg) injections will be given in two quadrants 180 degrees apart (total dose of 30 μL or 1,320 μg). Participants that still demonstrate active inflammation (incomplete or no response to initial injection) or experience a flare-up (as defined by a ≥1-step increase in scleral inflammation) after the initial injection will be eligible for a re-injection in the study eye at or after Week 4 (not to exceed a dose of 1,320 μg per eye within an eight-week period).

Based on this trial design, predict the completion outcome and termination type (if applicable).